WallStreetZenWallStreetZen

NASDAQ: RNAC
Cartesian Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RNAC

Based on 5 analysts offering 12 month price targets for Cartesian Therapeutics Inc

Min Forecast
$16.00+155.59%
Avg Forecast
$34.00+443.13%
Max Forecast
$44.00+602.88%

Should I buy or sell RNAC stock?

Based on 5 analysts offering ratings for Cartesian Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RNAC's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RNAC as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their RNAC stock forecasts and price targets.

RNAC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-10
lockedlocked$00.00+00.00%2026-03-09
lockedlocked$00.00+00.00%2026-03-09
lockedlocked$00.00+00.00%2025-11-19
lockedlocked$00.00+00.00%2025-11-14Find Out Why

1 of 1

Forecast return on equity

Is RNAC forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is RNAC forecast to generate an efficient return on assets?

Company
-25.09%
Industry
31.92%
RNAC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RNAC earnings per share forecast

What is RNAC's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$3.44
Avg 2 year Forecast
-$3.83
Avg 3 year Forecast
-$2.73

RNAC revenue forecast

What is RNAC's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$407.5k-85.43%
Avg 2 year Forecast
$407.5k-85.43%
Avg 3 year Forecast
$26.5M+847.23%
RNAC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNAC revenue growth forecast

How is RNAC forecast to perform vs Biotechnology companies and vs the US market?

Company
95.81%
Industry
38.7%
Market
13.79%
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNAC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNAC$6.26$34.00+443.13%Strong Buy
WHWK$3.51$7.00+99.43%Strong Buy
NKTX$2.32$11.33+388.49%Strong Buy
CDXS$1.82N/AN/A
ARTV$6.74$18.67+176.96%Buy
View Top Biotech Stocks

Cartesian Therapeutics Stock Forecast FAQ

Is Cartesian Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: RNAC) stock is to Strong Buy RNAC stock.

Out of 5 analysts, 2 (40%) are recommending RNAC as a Strong Buy, 3 (60%) are recommending RNAC as a Buy, 0 (0%) are recommending RNAC as a Hold, 0 (0%) are recommending RNAC as a Sell, and 0 (0%) are recommending RNAC as a Strong Sell.

If you're new to stock investing, here's how to buy Cartesian Therapeutics stock.

What is RNAC's earnings growth forecast for 2026-2028?

(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.

Cartesian Therapeutics's earnings in 2026 is -$130,302,000.On average, 11 Wall Street analysts forecast RNAC's earnings for 2026 to be -$91,161,883, with the lowest RNAC earnings forecast at -$98,719,605, and the highest RNAC earnings forecast at -$72,926,325. On average, 8 Wall Street analysts forecast RNAC's earnings for 2027 to be -$101,465,940, with the lowest RNAC earnings forecast at -$125,218,026, and the highest RNAC earnings forecast at -$75,571,926.

In 2028, RNAC is forecast to generate -$72,465,068 in earnings, with the lowest earnings forecast at -$69,623,301 and the highest earnings forecast at -$74,596,394.

What is RNAC's revenue growth forecast for 2026-2028?

(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual revenue growth rate of 95.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.

Cartesian Therapeutics's revenue in 2026 is $2,797,000.On average, 11 Wall Street analysts forecast RNAC's revenue for 2026 to be $10,802,162, with the lowest RNAC revenue forecast at $0, and the highest RNAC revenue forecast at $66,723,213. On average, 9 Wall Street analysts forecast RNAC's revenue for 2027 to be $10,802,162, with the lowest RNAC revenue forecast at $0, and the highest RNAC revenue forecast at $66,723,213.

In 2028, RNAC is forecast to generate $702,330,082 in revenue, with the lowest revenue forecast at $62,269,697 and the highest revenue forecast at $1,252,551,384.

What is RNAC's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RNAC) forecast ROA is -25.09%, which is lower than the forecast US Biotechnology industry average of 31.92%.

What is RNAC's Price Target?

According to 5 Wall Street analysts that have issued a 1 year RNAC price target, the average RNAC price target is $34.00, with the highest RNAC stock price forecast at $44.00 and the lowest RNAC stock price forecast at $16.00.

On average, Wall Street analysts predict that Cartesian Therapeutics's share price could reach $34.00 by Mar 10, 2027. The average Cartesian Therapeutics stock price prediction forecasts a potential upside of 443.13% from the current RNAC share price of $6.26.

What is RNAC's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RNAC) Cartesian Therapeutics's current Earnings Per Share (EPS) is -$5.02. On average, analysts forecast that RNAC's EPS will be -$3.44 for 2026, with the lowest EPS forecast at -$3.72, and the highest EPS forecast at -$2.75. On average, analysts forecast that RNAC's EPS will be -$3.83 for 2027, with the lowest EPS forecast at -$4.72, and the highest EPS forecast at -$2.85. In 2028, RNAC's EPS is forecast to hit -$2.73 (min: -$2.63, max: -$2.81).

What is RNAC's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RNAC) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.